SG11202102827YA - Treatment methods - Google Patents

Treatment methods

Info

Publication number
SG11202102827YA
SG11202102827YA SG11202102827YA SG11202102827YA SG11202102827YA SG 11202102827Y A SG11202102827Y A SG 11202102827YA SG 11202102827Y A SG11202102827Y A SG 11202102827YA SG 11202102827Y A SG11202102827Y A SG 11202102827YA SG 11202102827Y A SG11202102827Y A SG 11202102827YA
Authority
SG
Singapore
Prior art keywords
treatment methods
treatment
methods
Prior art date
Application number
SG11202102827YA
Other languages
English (en)
Inventor
Jessica Flechtner
Marie Lossky-Elias
Pamela Carroll
Hubert Lam
Lisa Mcneil
Wendy Broom
Original Assignee
Genocea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genocea Biosciences Inc filed Critical Genocea Biosciences Inc
Publication of SG11202102827YA publication Critical patent/SG11202102827YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SG11202102827YA 2018-09-27 2019-09-27 Treatment methods SG11202102827YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862737832P 2018-09-27 2018-09-27
US201862757915P 2018-11-09 2018-11-09
PCT/US2019/053672 WO2020069454A1 (en) 2018-09-27 2019-09-27 Treatment methods

Publications (1)

Publication Number Publication Date
SG11202102827YA true SG11202102827YA (en) 2021-04-29

Family

ID=69952327

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202102827YA SG11202102827YA (en) 2018-09-27 2019-09-27 Treatment methods

Country Status (13)

Country Link
US (1) US20230057310A1 (pt)
EP (1) EP3856241A4 (pt)
JP (1) JP2022502435A (pt)
KR (1) KR20210090618A (pt)
CN (1) CN113271970A (pt)
AU (1) AU2019351274A1 (pt)
BR (1) BR112021005221A2 (pt)
CA (1) CA3114585A1 (pt)
CO (1) CO2021005234A2 (pt)
IL (1) IL281839A (pt)
MX (1) MX2021003265A (pt)
SG (1) SG11202102827YA (pt)
WO (1) WO2020069454A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111491655A (zh) 2017-08-07 2020-08-04 加利福尼亚大学董事会 用于生成安全细胞治疗剂的平台
CN114621338B (zh) * 2022-03-11 2022-11-11 中山大学 一种mTOR抑制剂及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0893507A1 (en) * 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
KR100922031B1 (ko) * 1999-04-19 2009-10-19 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
WO2006039701A1 (en) * 2004-10-01 2006-04-13 University Of South Florida Flagellin-based adjuvants and vaccines
CN101663323A (zh) * 2006-12-27 2010-03-03 埃默里大学 用于治疗传染病和肿瘤的组合物和方法
TWI459955B (zh) * 2008-05-16 2014-11-11 Yeastern Biotech Co Ltd 一種活化樹突狀細胞和巨噬細胞的醫藥組合物
US8628785B2 (en) * 2008-05-16 2014-01-14 Yeastern Biotech Co., Ltd Method for augmenting the immunogenicity of an antigen
TWI389694B (zh) * 2008-12-23 2013-03-21 Intervet Int Bv 皂素或皂素與CpG之組合於誘發針對腫瘤特異性自體抗原之免疫反應之用途

Also Published As

Publication number Publication date
WO2020069454A1 (en) 2020-04-02
MX2021003265A (es) 2021-07-15
EP3856241A1 (en) 2021-08-04
CN113271970A (zh) 2021-08-17
BR112021005221A2 (pt) 2021-06-15
AU2019351274A1 (en) 2021-05-27
CA3114585A1 (en) 2020-04-02
JP2022502435A (ja) 2022-01-11
EP3856241A4 (en) 2022-10-05
CO2021005234A2 (es) 2021-07-19
KR20210090618A (ko) 2021-07-20
IL281839A (en) 2021-05-31
US20230057310A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
IL269371A (en) Treatment methods
IL282794A (en) therapeutic method
GB2567616B (en) Treatment method
GB201813876D0 (en) Treatment
GB201811679D0 (en) Treatment apparatus
IL281792A (en) Treatment methods
HUE056213T2 (hu) Kezelõ berendezés
GB2571601B (en) Treatment method
GB201800546D0 (en) Treatment
IL281839A (en) Treatment methods
SG11202001806TA (en) Treatment method
GB201808564D0 (en) Treatments
IL270867A (en) Treatment method
ZA202006321B (en) Treatments
GB201914296D0 (en) Treatment
SG10201913381PA (en) Treatment apparatus
GB201814905D0 (en) Treatment
GB201912760D0 (en) Treatment
GB201912335D0 (en) Treatment
GB201912365D0 (en) Treatment
GB201911816D0 (en) Treatment
GB201911603D0 (en) Treatment
GB201910755D0 (en) Treatment
GB201904253D0 (en) Treatment
GB201902579D0 (en) Treatment